http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0176559-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_10e4b1416c6e66e0ade5429212414964 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_faba5ffb12a63bef1b7a2c2bde762fb6 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-42 |
| filingDate | 2001-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_21ddc8474a1fb2c0ad9dae3d1070b213 |
| publicationDate | 2001-10-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-0176559-A1 |
| titleOfInvention | Method 0f administration of paclitaxel-plasma protein formulation |
| abstract | The present invention provides for a method for treating human or animal patients with paclitaxel formulation, the method comprising an intratumoral dose of a paclitaxel formulation and an intravenous dose of paclitaxel. The intravenous dose occurs about 1 to about 7 days after the intratumoral dose. The paclitaxel formulation may typically be either a paclitaxel/HSA formulation or paclitaxel/η-globulin formulation. |
| priorityDate | 2000-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 45.